Revvity has reported its Q2 results and the immediate reaction is the story — a 3.3% single-day drop to $111.39 on August 4, even as the stock's week-over-week loss remains a negligible 0.1%, and a dramatically changed options landscape now flags more defensiveness than the market carried heading into the print.
The options shift is the clearest signal this week. The put/call ratio has jumped to 0.47, running more than 2.5 standard deviations above its 20-day mean of 0.44 — the most defensive reading in recent months and a sharp break from the calm that prevailed ahead of earnings. That move suggests post-print hedging demand has picked up materially, even though the absolute PCR level remains modest. Short interest, by contrast, continues its well-documented retreat: it has eased another 1.7% over the past week to 6.3% of the free float, now down roughly 12% from the June peak. The borrow market confirms there is no squeeze tension — availability runs at 400%, meaning four shares remain available to lend for every one already borrowed, comfortably above the 52-week floor of 156%. Cost to borrow is a nominal 0.53%. Taken together, the derivatives market is pricing in some post-earnings uncertainty while short sellers continue to quietly exit — those two signals point in different directions, and that divergence is worth watching.
The peer backdrop sharpens the picture. BRKR fell a dramatic 21.8% on the day, with a weekly loss of 20%, after its own results rattled confidence across the life sciences tools group. TMO shed 1.6% on the day. ICLR dropped 13% on the week. Against that carnage, Revvity's 3.3% single-day decline and near-flat week look contained — but the sector clearly has incremental macro and demand headwinds to digest.
The analyst community has already begun reacting. Evercore ISI raised its target modestly to $126 this morning while maintaining its Outperform rating — a tweak rather than a conviction call, but directionally constructive coming immediately post-results. The broader analyst spread tells a more cautious story: the consensus mean target of $121 implies roughly 9% upside from current levels, but that figure masks a wide range. JP Morgan holds Neutral with a $90 target set back in May; Barclays sits at Equal-Weight with $105. Goldman Sachs cut to Neutral with a $95 target in April. On the other side, Baird and TD Cowen maintain Outperform and Buy ratings respectively with targets north of $120. Bernstein reinstated at Market Perform in late June with a $115 target. The bull case centers on TST-to-IGRA testing conversion and continued share gains in US autoimmune diagnostics. Bears point to China revenue erosion — projected at roughly 7% of total by 2025 and falling — plus industry funding pressure weighing on lab spending.
Valuation is undemanding relative to its own history. The stock trades at roughly 20x trailing earnings and 16x EV/EBITDA, with both multiples drifting slightly lower over the past 30 days. The 12-month forward EPS growth factor score ranks in the 95th percentile of the ORTEX universe — a signal that consensus estimates carry material upward revisions baked in — yet the short score of 52.7 and the low DTC rank of 14 suggest short sellers are not especially concerned either way. The ORTEX short score has been trending lower for two weeks, from 54.8 in late July to 52.7 now, consistent with the broader short interest reduction.
The next scheduled earnings event is November 5. Between now and then, the key variables are whether the post-results options defensiveness persists into next week, how the sector absorbs BRKR's sharp miss, and whether the Evercore target bump marks the start of a post-print analyst upgrade cycle or a lone constructive outlier.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
